EIR availability to manufacturers could prevent inappropriate warning letters, MDMA counsel Pilot says.
This article was originally published in The Gray Sheet
Executive Summary
GMP INSPECTION REPORT AVAILABILITY TO FIRMS PRIOR TO FDA ENFORCEMENT DECISION could help prevent inappropriate warning letters, Larry Pilot, McKenna & Cuneo attorney and counsel to the Medical Device Manufacturers Association, says in a May 24 letter to FDA. "Many manufacturers have experienced the trauma of a warning letter because of incorrect and uncontradicted statements made in" an establishment inspection report, Pilot says in the letter to Joseph Levitt, deputy director for regulations and policy at FDA's Center for Devices and Radiological Health. "These unfortunate experiences...could have been avoided if the manufacturer had access to and the opportunity to comment on the EIR prior to any enforcement decision by FDA."
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.